Skip to main content

Table 2 Univariate analysis of the association of lysozyme with relapse-free survival

From: Expression and prognostic significance of lysozyme in male breast cancer

  

Relapse-free survival (%)

 

Patient and tumor characteristics

n

5 years (% ± s.e.)

10 years (% ± s.e.)

P

Age

   

n.s.

   <60

16

100

66 ± 27

 

   ≥ 60

41

71 ± 8

71 ± 8

 

Tumor size

   

n.s.

   T1

20

76 ± 12

50 ± 2

 

   T2

19

94 ± 5

94 ± 5

 

   T3-T4

18

64 ± 13

-

 

Nodal status

   

<0.005

   N0

32

95 ± 4

95 ± 4

 

   N+

25

61 ± 11

41 ± 18

 

Histological grade

   

n.s.

   I

12

100

-

 

   II

25

81 ± 8

81 ± 8

 

   III

20

68 ± 12

41 ± 18

 

Lysozyme*

   

<0.05

   ≥ 100

25

64 ± 11

64 ± 11

 

   <100

84

93 ± 4

75 ± 17

 
  1. *Semiquantitive immunostaining score. s.e. = standard error; n.s. = not significant.